PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 116.84 M | 20.76 M | 355.88 M | 796.57 M | 377.55 M |
2022 | 56.81 M | -18,854,080 | 178.14 M | 665.59 M | 290.81 M |
2021 | 78.36 M | -136,750,456 | 200.98 M | 687.85 M | 383.33 M |
2020 | 64.2 M | 23.38 M | 229.25 M | 434.62 M | 207.92 M |
2019 | 40.98 M | 20.64 M | 180.02 M | 352.74 M | 164.92 M |